Zoetis Inc. $ZTS Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 203,999 shares of the company’s stock after selling 9,282 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Zoetis were worth $24,115,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the fourth quarter worth $25,000. Cassaday & Co Wealth Management LLC purchased a new position in Zoetis in the 1st quarter valued at $28,000. Lodestone Wealth Management LLC acquired a new position in Zoetis in the 4th quarter valued at $30,000. Root Financial Partners LLC raised its position in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the last quarter. Finally, Elyxium Wealth LLC purchased a new position in Zoetis during the 4th quarter worth $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Several firms announced or promoted securities-fraud litigation against Zoetis, which can weigh on sentiment by raising legal, financial, and reputational risk for the company. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class-action deadline reminders may keep the controversy in the spotlight and encourage more shareholder claims, adding overhang to the stock. ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th
• Neutral Sentiment: One Seeking Alpha commentary argues Zoetis sentiment remains strong and fundamentals are improving, offering a more constructive longer-term view. Zoetis: Sentiment Keeps Winning As Fundamentals Improve

Zoetis Stock Up 1.0%

ZTS stock opened at $75.32 on Friday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company’s 50 day simple moving average is $77.29 and its 200-day simple moving average is $104.25. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $160.48. The firm has a market capitalization of $31.58 billion, a PE ratio of 12.49, a P/E/G ratio of 1.16 and a beta of 0.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts expect that Zoetis Inc. will post 6.87 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is 35.16%.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Argus restated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. TD Cowen cut their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. UBS Group cut their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Finally, Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average price target of $119.50.

Insider Transactions at Zoetis

In related news, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Paul Bisaro acquired 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the transaction, the director owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 11,650 shares of company stock valued at $886,384 over the last three months. 0.22% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.